Physician profile
Sharon E Reid
NPI 1720618580
$3,445.99
in general payments reported to CMS, 2019-2025
13 companies · $1,383 in 2025
The $1,383 reported for 2025 was more than what 86% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $194 · 2022: $88.82 · 2023: $567 · 2024: $1,213 · 2025: $1,383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,040 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,039.67 |
| Education | $123.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $936.28 | 2021-2025 | Caplyta |
| Abbvie INC. | $545.67 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $432.12 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $378.62 | 2023-2025 | Invega Sustenna, Spravato |
| Axsome Therapeutics, INC. | $319.16 | 2024-2025 | Auvelity |
| Alkermes, INC. | $268.94 | 2021-2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $217.78 | 2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $88.66 | 2024-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $82.02 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Indivior INC. | $76.23 | 2023-2024 | Perseris |
| Vanda Pharmaceuticals INC. | $62.47 | 2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $23.06 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.98 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Reid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.